Although the p -value for precision (0.098) did not reach statistical significance—likely due to limited sample size—the latency increase ( p = 0.0399, d = 1.43) was both statistically and practically significant.
Although the lower prevalence of CR in the low-probability group compared with the intermediate- and high-probability groups did not reach statistical significance, the differences in CSFR between CDST response groups were statistically significant ( p = 0.04; Figure 2 ).
At stage 24, both the size of BB patches and the total number of BBs in deup1 morphants were mildly reduced relative to controls; however, this difference did not reach statistical significance ( P > 0.04; supplementary Fig. 5e, f ), suggesting that early BB formation and ciliogenesis are largely preserved during initial stages of epidermal development.
However, these associations did not reach statistical significance (OR = 1.09, 95% CI = 1.00 to 1.19, P = 0.04, and OR = 1.09, 95% CI = 1.01 to 1.17, P = 0.02, respectively).
Three studies assessed changes in femoral neck BMD, and the random-effects model showed an increasing trend (SMD = 0.24, 95% CI: −0.01–0.49), but this did not reach statistical significance, with moderate heterogeneity (I 2 = 70%, p = 0.04).
While the specific toothbrushing time categories did not reach statistical significance among children aged 6–8 years, the overall timing of brushing showed a significant relationship with lower caries prevalence ( p = 0.04), indicating a possible cumulative effect across all examined categories.
MLR, lymphocyte count, E/e’ ratio, LA volume and diastolic dysfunction did not reach statistical significance ( p > 0.04) and were therefore not included in our ROC analysis.
Adverse events and procedure times were lower in the FTRD ® group, although these differences did not reach statistical significance (4.44% vs. 15.5%, p = 0.04 and 25.6 ± 10.6 min vs. 76.7 ± 26.4 min, p ≤ 0.01).
Subgroup analysis stratified by treatment regimen revealed that the same cutoff value predicted a trend toward longer survival in patients receiving combination therapy; however, the results did not reach statistical significance for OS (PFS: p = 0.04, OS: p = 0.06).
When depression severity was categorized as no depression, mild, moderate, and severe, a trend toward an increased incidence of stroke in the moderate and severe depression groups was observed; however, this trend did not reach statistical significance (p=0.04) ( Table 1 ).
However, examination of the outer T cell-rich zone of mTLS showed higher mean densities of CD8 and PD-1 positive lymphocytes in the PT cases, although this did not reach statistical significance ( p = 0.040 and 0.029).
While there was a notable level of heterogeneity, it did not reach statistical significance ( I 2 = 97%, p = 0.04).
While this difference, and the presence of t(14;16) and deletion (17p), did not reach statistical significance, a higher number of patients in the early progression cohort had t(4:14) (21% vs. 8.9 %; P =0.04).
Response to lenzilumab was observed in the first through third quartiles of baseline CRP with the greatest lenzilumab treatment effect observed in the first quartile (CRP <41 mg/L; HR: 8.20; 95% CI 1.74 to 38.69; p=0.0079) and a numeric difference that did not reach statistical significance in the second quartile and a significant treatment effect observed in the third quartile (CRP 79<137 mg/L; HR: 2.25; 95% CI 1.04 to 4.88; p=0.0407 ( table 3 )).
Although most gastrointestinal symptoms did not reach statistical significance, early satiety ( p = 0.041) and functional deterioration ( p = 0.039) were significantly associated with irinotecan administration, while nausea ( p = 0.089) and vomiting ( p = 0.087) showed trends toward significance.
However, the DeLong test indicated that the AUC difference between the combined and clinical models did not reach statistical significance (P = 0.041), and the difference with the RDL model also did not reach significance (P > 0.05) ( Figures 3C ).
Interestingly, flatulence sensation paralleled intestinal gas evacuation and reverted to the level before administration, but the other sensations remained above pre-ingestion level; the differences between late ingestion and pre- ingestion levels were small and did not reach statistical significance, except for abdominal discomfort ( p = 0.041).
After 3 years' median follow-up, the PFS difference between atezolizumab and placebo did not reach statistical significance in the ITT (hazard ratio [HR], 0.83; 95% CI, 0.69 to 0.99; P = .041; median 13.5 v 11.3 months, respectively) or PD-L1–positive (HR, 0.86; 95% CI, 0.63 to 1.16; P = .30; median 15.2 v 13.1 months, respectively) populations.
Although the difference in Psychological Discomfort ( p = 0.094) did not reach statistical significance, the Functional Limitation domain stands out ( p = 0.041).
The mean serum P 4 level on the day of the hCG trigger was higher in the GnRHa group (2.54±1.56 ng/mL) than in the CC+hMG group (0.75±0.38 ng/mL); however, these results did not reach statistical significance ( p =0.041).
After 3 years’ median follow-up, the PFS difference between atezolizumab and placebo did not reach statistical significance (median 13.5 vs 11.3 months, HR=0.83; 95% CI=0.69–0.99; p=0.041) or in PD-L1-positive (median 15.2 vs 13.1 months, HR=0.86; 95% CI=0.63–1.16; p=0.300) populations.
In the peripheral analysis, there was a trend toward an enhancement of SNR after a-tDCS stimulation ( b = 0.014, P = 0.052), but it did not reach statistical significance; latency was increased after tACS ( b = 1.623, P = 0.041).
However, this result should be interpreted with caution, as the observed difference was small and did not reach statistical significance in the non-parametric analysis (Kruskal–Wallis, H(3) = 8.24, p = 0.0414; Dunn’s test BH-adjusted p = 0.1960).
33%) did not reach statistical significance, the treatment group showed later onset of recurrence (9.5 vs. 2.9 weeks, p = 0.042), a lower rate of advanced PVR ( p = 0.038), and significantly better final visual acuity outcomes ( p = 0.035) [ 51 ].
16 Unfortunately, the overall survival (OS) benefit of nivolumab compared to sorafenib did not reach statistical significance according to the pre-defined threshold in the trial design (HR, 0.84; P =0.042).